Icrucumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Icrucumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetVEGFR-1
Clinical data
SynonymsIMC-18F1
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6514H10024N1756O2032S42
Molar mass146.8 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.[1][2]

Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.[3]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.
  2. ^ LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs. 32 (2): 303–11. doi:10.1007/s10637-013-9998-8. PMID 23903897.
  3. ^ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov